secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001798749-23-000037
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics Q1 net loss $16.5M; Phase 2b topline data pushed to Q2 2024
--------------------------------------------------------------------------------

- Topline Phase 2b data from IMPAHCT trial of AV-101 now expected in Q2 2024; >100 sites in 20 countries.
- Cash, equivalents and short-term investments $118.9M at March 31, 2023; runway into H2 2025.
- Net loss $16.5M for Q1 2023 vs $10.9M Q1 2022; R&D expenses $13.5M (up from $7.3M).
- Enrollment pace increasing but slower than expected due to post-COVID factors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/0001798749-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000037/tmb-20230515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer